相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Adicet Bio secured FDA alignment to enable outpatient dosing of prulacabtagene leucel (prula-cel) for systemic lupus erythematosus and lupus nephritis patients, expanding treatment accessibility. - The company's Phase 1 autoimmune program now enrolls across seven disease cohorts with over 20 patients enrolled as of December 31, 2025, more than doubling since October data release. - Clinical updates from the prula-cel autoimmune program are expected in both halves of 2026, with plans to initiate a pivotal study in lupus nephritis or combined lupus conditions in the second half of 2026. - ADI-212, a next-generation gene-edited CAR-T therapy targeting prostate-specific membrane antigen, is advancing toward regulatory filing in the first half of 2026 for metastatic castration-resistant prostate cancer.
- DelveInsight's assessment reveals over 50 companies are actively developing 60+ advanced renal cell carcinoma therapies across various clinical phases. - Recent regulatory milestones include Innovent Biologics and HUTCHMED seeking approval for their sintilimab-fruquintinib combination following successful Phase II/III trial results. - Emerging therapies span multiple mechanisms including checkpoint inhibitors, antibody-drug conjugates, and targeted small molecules, with notable candidates like OATD-02, DS-6000a, and NKT2152 advancing through clinical development. - The pipeline demonstrates significant diversity in therapeutic approaches, with treatments categorized across oral, parenteral, and intravenous routes of administration.
- The global lupus nephritis market is projected to grow significantly by 2034, with the United States accounting for over 80% of the current $1.12 billion market share across major regions. - Several innovative therapies are advancing through clinical trials, including CAR-T cell treatments from companies like Allogene Therapeutics, Adicet Bio, and Caribou Biosciences, which received FDA Fast Track designations. - Key pharmaceutical players including Aurinia Pharmaceuticals, AstraZeneca, and Roche are developing treatments such as voclosporin, anifrolumab, and obinutuzumab to address the significant unmet needs in lupus nephritis management.
- DelveInsight's latest report reveals a robust pipeline with 20+ companies developing 22+ therapies for mantle cell lymphoma, highlighting significant advancement in treatment options for this rare blood cancer. - Recent approvals include AstraZeneca's CALQUENCE® (acalabrutinib) combination therapy for previously untreated MCL patients ineligible for stem cell transplantation, marking an important treatment milestone. - Key emerging therapies include Venetoclax (AbbVie), ADI-001 (Adicet Bio), and BGB-11417 (BeiGene), with multiple compounds targeting novel mechanisms of action across various clinical development stages.
- FDA regulatory actions in Q1 2025 include approval of Celltrion's denosumab biosimilars and Fast Track designation for CAR-T therapies targeting lupus, expanding treatment options for autoimmune conditions. - Breakthrough clinical data from the REGENCY trial demonstrates obinutuzumab's superior efficacy in lupus nephritis, while rosnilimab shows historic response rates in rheumatoid arthritis patients. - Novel approaches for difficult-to-treat conditions emerge with SAP-001 showing "best-in-class" results for refractory gout and transcranial magnetic stimulation providing sustained pain relief for fibromyalgia.
- The lupus nephritis clinical trial pipeline is robust, featuring over 30 companies developing more than 35 therapies. - Key players like AstraZeneca, Roche, and Novartis are advancing drugs such as Anifrolumab and Ianalumab through clinical trials. - Recent trial activities include Adicet Bio dosing the first patient in a Phase I trial of ADI-001 and Kyverna presenting updated clinical data on KYV-101. - Various therapeutic modalities, including monoclonal antibodies and cell therapies, are being explored across different clinical stages.
• The FDA cleared United Therapeutics' UKidney for US trials, a gene-edited porcine kidney product intended for end-stage renal disease via xenotransplant. • uniQure received the green light to proceed with the second dose cohort in their Phase 1/2 trial of AMT-162 for SOD1-ALS gene therapy. • Sarepta Therapeutics' Elevidys showed sustained benefit in ambulatory patients with Duchenne muscular dystrophy in Phase 3 trial results.
- Adicet Bio's ADI-001 receives FDA Fast Track designation for refractory systemic lupus erythematosus (SLE) with extrarenal involvement, expediting its development. - A Phase 1 trial is underway, evaluating ADI-001 across six autoimmune indications, including lupus nephritis (LN), SLE, systemic sclerosis (SSc), and others, with preliminary data expected in 2025. - ADI-001, an allogeneic gamma delta CAR T-cell therapy targeting CD20, has shown promising B-cell depletion in preclinical studies, suggesting potential as an off-the-shelf treatment. - Adicet Bio is also advancing ADI-270, a CAR T-cell therapy for metastatic clear cell renal cell carcinoma (ccRCC), with Phase 1 data anticipated in the first half of 2025.
• Adicet Bio has commenced a Phase 1 clinical trial for ADI-270, an allogeneic gamma delta CAR T-cell therapy, in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC). • ADI-270 targets CD70-positive cancers and is engineered to overcome the immunosuppressive tumor microenvironment, potentially offering a new treatment option for solid tumors. • The open-label, multicenter trial will assess the safety, tolerability, pharmacokinetics, and anti-tumor activity of ADI-270, with preliminary data expected in the first half of 2025. • The trial design includes dose escalation and expansion phases, allowing for a second dose of ADI-270 based on pre-defined criteria, to optimize treatment response.
• Adicet Bio has dosed the first lupus nephritis (LN) patient in its Phase 1 clinical trial evaluating ADI-001, an allogeneic gamma delta CAR T cell therapy. • The Phase 1 trial includes arms for systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), and stiff person syndrome (SPS); enrollment is expected to begin in Q1 2025. • Preliminary clinical data from the lupus nephritis arm of the Phase 1 trial is anticipated in the first half of 2025, offering a potential new treatment option. • ADI-001 has received Fast Track Designation from the FDA for relapsed/refractory class III or class IV lupus nephritis, highlighting the urgent need for new therapies.
